Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Clinical trial NCT04701060 · COMPLETED
Trial details
- NCT number
- NCT04701060
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-26
- Primary completion
- 2024-03-04
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.